Bisphosphonate Treatment of Osteogenesis Imperfecta

Completed · Phase 2

Conditions studied: Osteogenesis Imperfecta

In brief

The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.

Key facts

Study ID

NCT00063479

Run by

Novartis Pharmaceuticals

People needed

158

Starts

2003-06-01

Expected to finish

2007-05-01

Last updated by the study team

2017-06-01

Who can join

Age: 0 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA - Division of Pediatric Nephrology — Los Angeles, California, United States
• Alfred I. DuPont Hospital for Children — Wilmington, Delaware, United States
• Intermountain Orthopedics — Boise, Idaho, United States
• St. Jude Children's Research Hospital — Peoria, Illinois, United States
• Children's Hospital — Omaha, Nebraska, United States
• Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Children's Hospital — Columbus, Ohio, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Texas Children's Hosptial — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.